Journal of clinical lipidology最新文献

{"title":"The Impact of Statin Use on Sepsis Mortality","authors":"Mohan Li, R. Noordam, S. Trompet, Elizabeth M. Winter, J. Jukema, M. Sesmu Arbous, P. Rensen, S. Kooijman","doi":"10.1016/j.jacl.2024.07.006","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.07.006","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Experience with Familial Chylomicronemia Syndrome before and after Olezarsen Treatment: Qualitative Interviews with Clinical Trial Participants","authors":"T. M. Brown, Emily Bratlee-Whitaker, Marcello Arca, A. Baass, Seth J Baum, O. M. Grijalvo, Jean Bergeron, D. Gaudet, Veronica Alexander, Montserrat Vera Llonch, Sheri Fehnel, S. Tsimikas, A. S. Kessler","doi":"10.1016/j.jacl.2024.04.105","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.04.105","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes","authors":"Zhenqian Wang, Jiaying Zhang, Fengwei Jiao, Yueheng Wu, Liyuan Han, Guozhi Jiang","doi":"10.1016/j.jacl.2024.07.004","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.07.004","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of genetically-influenced phospholipid transfer protein activity in lipoprotein metabolism and coronary artery disease","authors":"","doi":"10.1016/j.jacl.2024.03.007","DOIUrl":"10.1016/j.jacl.2024.03.007","url":null,"abstract":"<div><h3>BACKGROUND</h3><p>Phospholipid transfer protein (PLTP) transfers surface phospholipids between lipoproteins and as such plays a role in lipoprotein metabolism, but with unclear effects on coronary artery disease (CAD) risk. We aimed to investigate the associations of genetically-influenced PLTP activity with 1-H nuclear magnetic resonance (¹H-NMR) metabolomic measures and with CAD. Furthermore, using factorial Mendelian randomization (MR), we examined the potential additional effect of genetically-influenced PLTP activity on CAD risk on top of genetically-influenced low-density lipoprotein-cholesterol (LDL-C) lowering.</p></div><div><h3>METHODS</h3><p>Using data from UK Biobank, genetic scores for PLTP activity and LDL-C were calculated and dichotomised based on the median, generating four groups with combinations of high/low PLTP activity and high/low LDL-C levels for the factorial MR. Linear and logistic regressions were performed on 168 metabolomic measures (<em>N</em> = 58,514) and CAD (<em>N</em> = 318,734, N-cases=37,552), respectively, with results expressed as <em>β</em> coefficients (in standard deviation units) or odds ratios (ORs) and 95% confidence interval (CI).</p></div><div><h3>RESULTS</h3><p>Irrespective of the genetically-influenced LDL-C, genetically-influenced low PLTP activity was associated with a higher high-density lipoprotein (HDL) particle concentration (<em>β</em> [95% CI]: 0.03 [0.01, 0.05]), smaller HDL size (-0.14 [-0.15, -0.12]) and higher triglyceride (TG) concentration (0.04 [0.02, 0.05]), but not with CAD (OR 0.99 [0.97, 1.02]). In factorial MR analyses, genetically-influenced low PLTP activity and genetically-influenced low LDL-C had independent associations with metabolomic measures, and genetically-influenced low PLTP activity did not show an additional effect on CAD risk.</p></div><div><h3>CONCLUSIONS</h3><p>Low PLTP activity associates with higher HDL particle concentration, smaller HDL particle size and higher TG concentration, but no association with CAD risk was observed.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1933287424000436/pdfft?md5=b171e8f09e2e29fe1ddb0b0aec5ec584&pid=1-s2.0-S1933287424000436-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140404578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD)","authors":"","doi":"10.1016/j.jacl.2024.03.003","DOIUrl":"10.1016/j.jacl.2024.03.003","url":null,"abstract":"<div><h3>BACKGROUND</h3><p>Non-alcoholic fatty liver disease (NAFLD) is an independent risk factor for cardiovascular disease (CVD). Statins are recommended for treatment of dyslipidemia to reduce the overall cardiovascular risk in patients with NAFLD. However, statin treatment was underutilized and the effect of statins on liver enzymes remained unclear in this patient population.</p></div><div><h3>OBJECTIVES</h3><p>This study aimed to provide real-world evidence of the safety and effect of statin use in patients with NAFLD.</p></div><div><h3>METHODS</h3><p>We conducted a cross-sectional survey study of adults with NAFLD using pooled data from the US NHANES database 2009–2018. NAFLD was defined by Fatty Liver Index (FLI) ≥ 60 and United States Fatty Liver Index (USFLI) ≥ 30. Multivariate regression analyses adjusted for baseline clinical and demographic characteristics were performed to compare the liver enzymes and lipid profile between statin and non-statin users.</p></div><div><h3>RESULTS</h3><p>The study included 2,533 adults with NAFLD, representing 22.6 million individuals in the US, with 27% receiving statin treatment between 2009 and 2018. The mean differences of liver enzymes for AST, ALT, ALP, and GGT between statin and non-statin users were -0.86 (p=0.539), -3.49 (p=0.042), -0.25 (p=0.913), and 0.57 (p=0.901), respectively. In individuals with NAFLD and dyslipidemia, total cholesterol and LDL levels were significantly lower in statin users compared to non-statin users (mean difference, -28.9; p&lt;0.001 and -27.7; p&lt;0.001).</p></div><div><h3>CONCLUSION</h3><p>The use of statins was not associated with elevated liver enzymes in patients with NAFLD. Significantly lower levels of ALT, total cholesterol, and LDL were observed in statin users compared to non-statin users.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1933287424000357/pdfft?md5=58c0893f7293309aa8318154d95f1087&pid=1-s2.0-S1933287424000357-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140203459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Intensity Statins vs. Moderate-Intensity Statin-Ezetimibe Combination Therapy: A Patient Centered Approach","authors":"Jelani K Grant, C. Orringer","doi":"10.1016/j.jacl.2024.07.007","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.07.007","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141844649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Outcomes Unveiled: Bempedoic Acid in Hyperlipidemia—A Comprehensive Updated Systematic Review and Meta-analysis of RCTs","authors":"Saba Ali, Muhammad Sohaib Asghar, Chad Brands, Thomas Shimshak, L. Colaco","doi":"10.1016/j.jacl.2024.04.106","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.04.106","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"†Age- and Sex-Specific Nomographic CT Quantitative Plaque Data From a Large International Cohort","authors":"G. Tzimas, Gaurav Gulsin, MB ChB, Nicholas Ng, S. Mullen, Stephanie Sellers, Philipp Blanke, J. Leipsic","doi":"10.1016/j.jacl.2024.04.118","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.04.118","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography","authors":"Bradley Brown, David Watson, Wess Boatwright, Thomas Dayspring, Michael Barnes, Szilard Voros","doi":"10.1016/j.jacl.2024.04.117","DOIUrl":"https://doi.org/10.1016/j.jacl.2024.04.117","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"†Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates","authors":"","doi":"10.1016/j.jacl.2024.04.099","DOIUrl":"10.1016/j.jacl.2024.04.099","url":null,"abstract":"<div><h3>Study Funding</h3><p>NewAmsterdam Pharma.</p></div><div><h3>Background/Synopsis</h3><p>Previous CETP inhibitors were highly lipophilic with logP of 7.2–9.2, leading to adipose tissue accumulation in the case of anacetrapib. In contrast, obicetrapib is characterized by a logP of 4.9 and terminal half-life of ∼135 hours.</p></div><div><h3>Objective/Purpose</h3><p>Studies in cynomolgus monkeys and humans were undertaken to determine the definitive elimination of obicetrapib from these organisms.</p></div><div><h3>Methods</h3><p>In a 9-month toxicology study in cynomolgus monkeys, obicetrapib was administered at doses up to 50 mg/kg/day. A phase 1 trial administered doses of 1-25 mg to healthy humans, and 3, placebo-controlled, phase 2 studies in dyslipidemic humans administered obicetrapib (on background statin therapy) at 5 or 10 mg/d for 8 weeks (ROSE; n=120), 10 mg/d monotherapy or with ezetimibe for 12 weeks (ROSE2; n=119), and 2.5, 5, or 10 mg/d for 8 weeks (Japan; n=102). Plasma concentrations of obicetrapib were measured during dosing/treatment and up to 15-weeks post-treatment.</p></div><div><h3>Results</h3><p>In monkeys, obicetrapib was not detected in any adipose tissue samples and a recovery period of 13 weeks was sufficient for complete elimination from systemic circulation. The terminal half-life of obicetrapib was between 121 and 151 hours in healthy humans. In ROSE, median plasma obicetrapib in the 10 mg/d group was 384 mg/L at week 8 and decreased by 93, 98, and 99% at 4-, 8-, and 15-weeks post-treatment. In ROSE2, median plasma obicetrapib at week 12 was 387 mg/L in the 10 mg/d monotherapy group and decreased by 94% at 4-weeks post-treatment. In the Japan phase 2 study, median plasma obicetrapib at week 8 was 472 mg/L for the 10 mg/d group and decreased by 96% at 4-weeks post-treatment.</p></div><div><h3>Conclusions</h3><p>In dedicated pre-clinical experiments and in clinical trials, obicetrapib shows no evidence of accumulation in adipose tissue or delayed elimination from the systemic circulation supporting once daily, chronic dosing of 10 mg.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}